Volume 14, Number 2—February 2008
Research
Cost-effectiveness of Human Papillomavirus Vaccination in the United States
Table 1
Estimated cost per QALY gained by adding routine HPV vaccination of 12-y-old girls to existing cervical cancer screening in the United States*
Parameter | Population model |
Cohort model; no herd immunity, $US | |
---|---|---|---|
No herd immunity, $US | Herd immunity, $US | ||
Excluding anal, vaginal, vulvar, and oropharyngeal cancers | |||
Vaccine targets HPV types 6,11,16,18 | 10,294 | 5,336 | 8,593 |
Vaccine targets HPV types 16,18 |
14,723 |
10,318 |
12,562 |
Including anal, vaginal, vulvar, and orophayngeal cancers† | |||
Vaccine targets HPV types 6,11,16,18 | 8,137 | 3,906 | 6,430 |
Vaccine targets HPV types 16,18 | 11,602 | 7,848 | 9,471 |
*When applying base-case parameter values to 12 model variations. QALY, quality-adjusted life year; HPV, human papillomavirus.
†The oropharyngeal cancer sites we included were base of tongue, tonsillar, and other sites as described in the Technical Appendix.